Raju Prasad
Stock Analyst at William Blair
(0.10)
# 4,495
Out of 5,154 analysts
9
Total ratings
25%
Success rate
-34.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Raju Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DTIL Precision BioSciences | Downgrades: Market Perform | n/a | $4.61 | - | 1 | Jun 9, 2022 | |
| NTLA Intellia Therapeutics | Initiates: Outperform | n/a | $13.44 | - | 1 | Feb 18, 2022 | |
| ASMB Assembly Biosciences | Downgrades: Market Perform | n/a | $28.27 | - | 1 | Sep 2, 2021 | |
| TSHA Taysha Gene Therapies | Initiates: Outperform | $46 | $4.57 | +906.56% | 1 | Feb 24, 2021 | |
| CRSP CRISPR Therapeutics AG | Initiates: Market Perform | n/a | $56.50 | - | 1 | Mar 14, 2019 | |
| BOLD Boundless Bio | Downgrades: Market Perform | n/a | $1.13 | - | 2 | Nov 7, 2018 | |
| PTCT PTC Therapeutics | Upgrades: Outperform | n/a | $62.82 | - | 2 | Jun 18, 2018 |
Precision BioSciences
Jun 9, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $4.61
Upside: -
Intellia Therapeutics
Feb 18, 2022
Initiates: Outperform
Price Target: n/a
Current: $13.44
Upside: -
Assembly Biosciences
Sep 2, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $28.27
Upside: -
Taysha Gene Therapies
Feb 24, 2021
Initiates: Outperform
Price Target: $46
Current: $4.57
Upside: +906.56%
CRISPR Therapeutics AG
Mar 14, 2019
Initiates: Market Perform
Price Target: n/a
Current: $56.50
Upside: -
Boundless Bio
Nov 7, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $1.13
Upside: -
PTC Therapeutics
Jun 18, 2018
Upgrades: Outperform
Price Target: n/a
Current: $62.82
Upside: -